QUBT is in a sustained downtrend over the past year, with a 1-year price change of -56.17%. The current price of $9.05 sits at 14.6% of its 52-week range (low $6.18, high $25.84), indicating it is near the lows. This positioning suggests the stock is deeply out of favor and potentially oversold, but also reflects a lack of positive momentum and risk of further decline. The 52-week high of $25.84 represents a significant resistance level, while the low of $6.18 provides a support floor. With a beta of 3.78, the stock is nearly 4 times more volatile than the S&P 500, amplifying both upside and downside risks. A breakout above $25.84 would signal a major trend reversal, while a breakdown below $6.18 could trigger further selling. The 1-month price change of -26.12% sharply contrasts with the 3-month change of +31.73%, indicating a recent sharp pullback after a strong rally. This divergence suggests the stock is experiencing a volatile correction within a longer-term downtrend. The 1-month relative strength of -24.87% versus the S&P 500 confirms underperformance, while the 3-month relative strength of +18.17% shows the prior rally was sector-driven. The RSI is not provided, but the rapid decline from May highs to July lows implies oversold conditions, though momentum remains negative. The 52-week low of $6.18 and high of $25.84 define the trading range. The stock is currently 65% below its 52-week high, reflecting deep bearish sentiment. A move above $10.50 (recent June high) could signal short-term stabilization, while a break below $9.00 (current level) risks testing the $6.18 low. With a beta of 3.78, the stock's volatility is extreme, meaning it can move 3.78% for every 1% move in the S&P 500, requiring strict risk management.

Revenue remains minuscule but showed a YoY increase of 219.35% in the most recent quarter (Q4 2025) to $198,000, though this is from a very low base. The multi-quarter trend is erratic: Q1 2025 revenue was $39,000, Q2 $61,000, Q3 $384,000, and Q4 $198,000. The Q3 spike was driven by a one-time contract, while Q4 normalized. The company is still pre-commercial, with no clear recurring revenue stream. The investment case hinges on future commercialization, but current revenue does not support the valuation. The company is unprofitable, with a net loss of -$1.556 million in Q4 2025, though this is a significant improvement from -$51.237 million in Q4 2024. Gross margin was negative at -49.49% in Q4 2025, meaning the cost of revenue exceeds revenue, though this improved from -826% in Q4 2024. Operating margin was -112.2%, indicating heavy R&D and SG&A spending. The trajectory toward profitability is unclear, as the company is still investing heavily in development. The balance sheet shows a strong cash position of $737.88 million as of Q4 2025, up from $78.945 million a year earlier, due to a massive $718.6 million equity offering. Debt is negligible (debt-to-equity of 0.0011), and the current ratio is 102.38, indicating ample liquidity. However, free cash flow was negative -$12.172 million in Q4 2025 and -$36.984 million TTM, meaning the company is burning cash. The cash runway is long, but dilution risk is high given the reliance on equity financing. ROE is -0.0117%, reflecting the net loss relative to equity.